Ultragenyx Pharmaceutical (RARE) EPS (Weighted Average and Diluted) Growth (1y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -82.39% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -97.49% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -79.34% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 61.45% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -7.15% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1,178.57% |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | -17.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.20% |
| Dec 31, 2025 | 7.25% |
| Sep 30, 2025 | -29.29% |
| Jun 30, 2025 | 23.03% |
| Mar 31, 2025 | 22.66% |
| Dec 31, 2024 | 4.17% |
| Sep 30, 2024 | 37.22% |
| Jun 30, 2024 | 32.44% |
| Mar 31, 2024 | 12.88% |
| Dec 31, 2023 | 33.33% |
| Sep 30, 2023 | 36.29% |
| Jun 30, 2023 | 0.44% |
| Mar 31, 2023 | -6.39% |
| Dec 31, 2022 | -20.67% |
| Sep 30, 2022 | -224.07% |
| Jun 30, 2022 | -24.86% |
| Dec 31, 2021 | -353.60% |
| Jun 30, 2021 | -541.46% |
| Mar 31, 2019 | -393.55% |
| Mar 31, 2018 | 138.04% |